Hostname: page-component-77c89778f8-gq7q9 Total loading time: 0 Render date: 2024-07-24T10:29:09.911Z Has data issue: false hasContentIssue false
  • English
  • Français

Efectos de los tratamientos con antipsicóticos atípicos y típicos en la función sexual en los pacientes con esquizofrenia: resultados al año del Estudio Intercontinental de Evolución de la Salud de Pacientes Ambulatorios con Esquizofrenia (IC-SOHO)

Published online by Cambridge University Press:  12 May 2020

Martin Dossenbach ,
Yulia Dyachkova ,
Sebnem Pirildar ,
Martin Anders ,
Afaf Khalil ,
Aleksander Araszkiewicz ,
Tamara Shakhnovich ,
Aly Akram ,
Jan Pecenak  and
Margaret McBride
...Show all authors
Martin Dossenbach
Affiliation:
Eli Lilly and Company, Ges.m.b.H, Kölblgasse 8-10, 1030 Viena, Austria
Yulia Dyachkova
Affiliation:
Eli Lilly and Company, Ges.m.b.H, Kölblgasse 8-10, 1030 Viena, Austria
Sebnem Pirildar
Affiliation:
Universidad Ege, Facultad de Medicina, Departamento de Psiquiatría, Izmir, Turquía
Martin Anders
Affiliation:
Departamento de Psiquiatría, Primera Facultad de Medicina, Universidad Carlos, Ke Karlovu 11, 120 00 Praga 2, República Checa
Afaf Khalil
Affiliation:
Hospital Universitario Ein Shames, Departamento de Psiquiatría, Heliópolis, Cairo, Egipto
Aleksander Araszkiewicz
Affiliation:
Departamento de Psiquiatría, Facultad de Medicina de la Universidad de Bydgoszcz, Polonia
Tamara Shakhnovich
Affiliation:
Hospital Psiquiátrico N4, 3 Poteshnaya Str., 123298, Moscú, Rusia
Aly Akram
Affiliation:
Hospital Suliman Faqueeh, Jeddah, Arabia Saudí
Jan Pecenak
Affiliation:
Departamento de Psiquiatría, Facultad de Medicina, Universidad Comenius, Hospital Universitario de Bratislava, Mickiewiczova 13, 81369Bratislava, Eslovaquia
Margaret McBride
Affiliation:
Eli Lilly and Company, Sydney, Australia
Tamas Treuer
Affiliation:
Eli Lilly and Company, Ges.m.b.H, Kölblgasse 8-10, 1030 Viena, Austria
Get access

Resumen

Propósito.

La disfunción sexual en los pacientes con esquizofrenia puede reducir la calidad de vida y el cumplimiento del tratamiento. Este informe comparará los efectos de antipsicóticos atípicos y típicos seleccionados sobre la función sexual en una gran población internacional de pacientes ambulatorios con esquizofrenia que recibieron tratamiento durante más de un año.

Sujetos y métodos.

Se clasificó a pacientes ambulatorios con esquizofrenia que iniciaron tratamiento antipsicótico o lo cambiaron y se incorporaron a este estudio prospectivo observacional de 3 años según la monoterapia prescrita en la línea de base: olanzapina (n = 2.638), risperidona (n = 860), quetiapina (n = 142) o haloperidol (n = 188).

Resultados.

Basado en la percepción del paciente, la probabilidad de experimentar disfunción sexual durante 1 año de terapia era significativamente más baja para los pacientes tratados con olanzapina y quetiapina cuando se comparaba con pacientes que recibían risperidona o haloperidol (todas las P ≤ 0,001). Las mujeres con olanzapina (14%) o quetiapina (8%) experimentaban una tasa inferior de irregularidades menstruales, comparado con las mujeres con risperidona (23%) o haloperidol (29%). Se puso de manifiesto una discordancia significativa entre los informes de los pacientes y la percepción del psiquiatra de la disfunción sexual, subestimando los psiquiatras la disfunción sexual (P ≤ 0,001).

Conclusiós.

Estos hallazgos indican que existen diferencias clínicamente relevantes en los perfiles de efectos secundarios sexuales de estos antipsicóticos seleccionados. Se debe considerar estos factores al seleccionar el tratamiento más apropiado para los pacientes ambulatorios con esquizofrenia.

Keywords

EsquizofreniaDisfunción sexualHiperprolactinemiaAgentes antipsicóticos
Type
Original
Information
European Psychiatry (Ed. Española) , Volume 13 , Issue 8 , November 2006 , pp. 380 - 388
Copyright
Copyright © European Psychiatric Association 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

Aizenberg, DZemishlany, ZDorfman-Etrog, PWeizman, A. Sexual dysfunction in mole schizophrenic patients. J Clin Psychiatry 1995;56:137–41.Google Scholar
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: APA; 1994.Google Scholar
Arvanitis, LAMiller, BG. Seroquel Trial 13 Study Group. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233–46.CrossRefGoogle Scholar
Bobes, JGarcia-Portilla, MPRejas, JHernandez, GGarcia-Garcia, MRico-Villademoros, F, et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther 2003;29:125–47.CrossRefGoogle ScholarPubMed
Compton, MTMiller, AH. Sexual side effects associated with conventional and atypical antipsychotics. Psychopharmacol Bull 2001; 35:89–108.Google ScholarPubMed
Cutler, AJ. Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology 2003;28:69–82.CrossRefGoogle ScholarPubMed
David, STaylor, CKinon, BBreier, A. The effects of olanzapine, risperidone and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000;22:1085–96.CrossRefGoogle ScholarPubMed
Dickson, RAGlazer, WM. Neuroleptic-induced hyperprolactinemia. Schizophr Res 1999;35(Suppl):75–86.CrossRefGoogle ScholarPubMed
Dickson, RASeeman, MVCorenblum, B. Hormonal side effects in women: typical versus atypical antipsychotic treatment. J Clin Psychiatry 2000; 13(Suppl):23–30.Google Scholar
Dossenbach, MErol, Ael Mahfoud Kessaci, MShahen, MOSunbol, MMBoland, J, et al. Effectiveness of antipsychotic treatments for schizophrenia—analysis from a prospective observational study (ICSOHO) comparing olanzapine, quetiapine, risperidone and haloperidol. J Clin Psychiatry 2004;65:312–21.CrossRefGoogle Scholar
Dossenbach, MHodge, AAnders, MMolnár, BPecinkaitiene, DKrupka-Matuszczyk, I, et al. Prevalence of sexual dysfunction in patients with schizophrenia: intemational variation and underestimation. Int J Neuropsychopharmacol 2005;8:195–201.CrossRefGoogle Scholar
Fleischhacker, WWMeise, UGunther, VKurz, M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand 1994;382(Suppl):11–5.Google ScholarPubMed
Friedman, SHarrison, G. Sexual histories, attitudes, and behaviour of schizophrenic and “normal” women. Arch Sex Behav 1984; 13: 555–67.CrossRefGoogle ScholarPubMed
Ghadirian, AMChouinard, GAnnable, L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis 1982; 170 :463–7.CrossRefGoogle ScholarPubMed
Halbreich, UKinon, BJGilmore, JAKahn, LS. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003;28(Suppl):53–67.CrossRefGoogle ScholarPubMed
Kim, KSPae, CUChae, JHBahk, WMJun, TYKim, DJ, et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry 2003;63: 408–13.CrossRefGoogle Scholar
Kinon, BJGilmore, JALiu, HHalbreich, UM. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003;28:55–68.CrossRefGoogle ScholarPubMed
Kleinberg, DLDavis, JMde Coster, RVan Baelen, BBrecher, MProlactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999;19:57–61.CrossRefGoogle ScholarPubMed
Knegtering, HBlijd, CBoks, MPM. Sexual dysfunctions and prolactin levels in patients using classical antipsychotics, risperidone or olanzapine. Schizophr Res 1999;36:355–6.Google Scholar
Knegtering, Hvan der Moolen, AECastelein, SKluiter, Hvan den Bosch, RJWhat are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology 2003; 28:109–23.CrossRefGoogle ScholarPubMed
Lingjaerde, OAhlfors, UGBech, PDencker, SJElgen, K. The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs, and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987(Suppl. 76):1–100.CrossRefGoogle Scholar
Maguire, GA. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 2002;63(Suppl 4):56–62.Google ScholarPubMed
Meany, AMO'Keane, V. Prolactin and schizophrenia: clinical consequences of hyperprolactinaemia. Life Sci 2002;71:979–92.CrossRefGoogle Scholar
Perkins, DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121–8.CrossRefGoogle ScholarPubMed
Peuskens, JSienaert, P, De Hert, M. Sexual dysfunction: the unspoken side effect of antipsychotics. Eur Psychiatry 1998;13(Suppl 1):23–30.CrossRefGoogle ScholarPubMed
Raja, MAzzoni, A. Sexual behavior and sexual problems among patients with severe chronic psychoses. Eur Psychiatry 2003;18:70–6.CrossRefGoogle ScholarPubMed
Sacristan, JAGomez, JCMontejo, ALVieta, EGregor, KJ. Doses of olanzapine, risperidone and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiológico en la Esquizofrenia con Olanzapina. Clin Ther 2000;22:583–99.CrossRefGoogle Scholar
Tran, PVHamilton, SHKumiz, AJPotvin, JHAndersen, SWBeasley, C, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407–18.CrossRefGoogle ScholarPubMed
Volavka, JCzobor, PCooper, TBSheitman, BLindenmayer, JPCitrome, L, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 2004;65:57–61.CrossRefGoogle ScholarPubMed
World Health Organization. The ICD-10 Classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: WHO; 1992.Google Scholar